Use of placental stem cells in treatment of acute kidney injury

Abstract

Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).

1 . A method of treating acute kidney injury (AKI) in a subject having AKI comprising administering to the subject a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms or complications of AKI, or a reduction in the progression of one or more symptoms or complications of AKI, in the subject. 
     
     
         2 . A method of preventing one or more symptoms or complications associated with acute kidney injury (AKI) in a subject having AKI comprising administering to the subject a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to prevent the onset of one or more symptoms or complications of AKI in the subject. 
     
     
         3 . The method of  claim 1 , wherein said placental stem cells are CD10 + , CD34 − , CD105 + , CD200 +  placental stem cells. 
     
     
         4 . The method of  claim 3 , wherein said placental stem cells express OCT-4. 
     
     
         5 . The method of  claim 4 , wherein said placental stem cells are additionally CD45− and CD90+. 
     
     
         6 . The method of  claim 5 , wherein said placental stem cells are additionally CD80− and CD86−. 
     
     
         7 . The method of  claim 1 , wherein the symptom associated with AKI is fatigue, bloody stool, bad breath, metallic taste in the mouth, bruising, hand tremor, high blood pressure, nosebleeds, hiccups, seizures, shortness of breath, changes in urination pattern (e.g., loss of ability to urinate regularly, or frequent urination at night), loss of appetite, headache, nausea and vomiting, irregular heartbeat, pain in the flanks (e.g., caused by thrombosis of the renal blood vessels or inflammation of the kidney), thirst, palpable bladder, accumulation of fluid in the limbs (peripheral edema) and the lungs (pulmonary edema), and/or cardiac tamponade. 
     
     
         8 . The method of  claim 1 , wherein said method results in an increase in glomerular filtration rate, a decrease in serum creatinine level, a decrease in urine creatinine level, an increase in creatinine clearance, a decrease in the level of blood urea nitrogen (BUN), and/or a decrease in fractional excretion of sodium in the subject. 
     
     
         9 . The method of  claim 1 , wherein said placental stem cells are administered systemically, intravenously, intraarterially, or locally. 
     
     
         10 . The method of  claim 2 , wherein said placental stem cells are CD10 + , CD34 − , CD105 + , CD200 +  placental stem cells. 
     
     
         11 . The method of  claim 10 , wherein said placental stem cells express OCT-4. 
     
     
         12 . The method of  claim 11 , wherein said placental stem cells are additionally CD45− and CD90+. 
     
     
         13 . The method of  claim 12 , wherein said placental stem cells are additionally CD80− and CD86−. 
     
     
         14 . The method of  claim 2 , wherein the symptom associated with AKI is fatigue, bloody stool, bad breath, metallic taste in the mouth, bruising, hand tremor, high blood pressure, nosebleeds, hiccups, seizures, shortness of breath, changes in urination pattern (e.g., loss of ability to urinate regularly, or frequent urination at night), loss of appetite, headache, nausea and vomiting, irregular heartbeat, pain in the flanks (e.g., caused by thrombosis of the renal blood vessels or inflammation of the kidney), thirst, palpable bladder, accumulation of fluid in the limbs (peripheral edema) and the lungs (pulmonary edema), and/or cardiac tamponade. 
     
     
         15 . The method of  claim 2 , wherein said method results in an increase in glomerular filtration rate, a decrease in serum creatinine level, a decrease in urine creatinine level, an increase in creatinine clearance, a decrease in the level of blood urea nitrogen (BUN), and/or a decrease in fractional excretion of sodium in the subject. 
     
     
         16 . The method of  claim 2 , wherein said placental stem cells are administered systemically, intravenously, intraarterially, or locally.